US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Telix Pharmaceuticals Ltd. (Uplisting)

11.33

-1.0900-8.78%

Post-market: 11.400.0700+0.62%19:30 EDT

Volume:299.63K

Turnover:3.40M

Market Cap:3.84B

PE:-536.97

High:11.39

Open:11.34

Low:11.19

Close:12.42

52wk High:12.60

52wk Low:6.28

Shares:339.00M

Float Shares:272.00M

Volume Ratio:2.20

T/O Rate:0.11%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0211

EPS(LYR):-0.0211

ROE:7.36%

ROA:2.71%

PB:7.88

PE(LYR):-536.97

Loading ...

Overview Company News Filings

Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies

MT Newswires Live

Why Is Telix Pharma Stock Soaring Tuesday?

Benzinga Earnings

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline

MT Newswires Live

Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.

Telix Pharmaceuticals Q1 Revenue Rises 24%; Shares Gain 6%

MT Newswires Live

Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLPPF)

Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?

Simply Wall St.

Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals

Telix Appoints David Gill as Non-Executive Director

Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?

Simply Wall St.

ASX Growth Companies With Insider Ownership Up To 38%

Simply Wall St.

A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates

Simply Wall St.

Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?

Simply Wall St.

Telix Pharmaceuticals Says Citigroup Lifts Stake

MT Newswires Live

Telix Issues New Deferred Share Rights Under Employee Incentive Scheme

UBS Remains a Buy on Telix Pharmaceuticals (TLPPF)

Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)

Telix Resubmits U.S. FDA Application for Glioma Imaging Agent TLX101-Px

A Look At Telix Pharmaceuticals’ Valuation After ProstACT Global Phase 3 TLX591-Tx Milestone

Simply Wall St.

Telix Pharmaceuticals (ASX:TLX) Is Up 11.3% After Positive Phase 3 TLX591-Tx Safety Data - What's Changed

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/stock/TLX/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"TLX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","market":"US","secType":"STK","nameCN":"Telix Pharmaceuticals Ltd. (Uplisting)","latestPrice":11.33,"timestamp":1787342400000,"preClose":12.42,"halted":0,"volume":299625,"hourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"delay":0,"changeRate":-0.08776167471819644,"floatShares":272000000,"shares":339000000,"eps":-0.0211,"marketStatus":"Market Closed","change":-1.09,"latestTime":"08-21 16:00:00 EDT","open":11.34,"high":11.39,"low":11.19,"amount":3395453.5710000005,"amplitude":0.016103,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0211,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"adrRate":1,"listingDate":1718337600000,"exchange":"NASDAQ","adjPreClose":12.42,"preHourTrading":{"tag":"盘前","latestPrice":11.3,"preClose":12.42,"latestTime":"09:29 EDT","volume":9930,"amount":113052.21588,"timestamp":1787318999999,"change":-1.12,"changeRate":-0.090177,"amplitude":0.02818},"postHourTrading":{"tag":"盘后","latestPrice":11.4,"preClose":11.33,"latestTime":"19:30 EDT","volume":497,"amount":5666.12,"timestamp":1787355007152,"change":0.07,"changeRate":0.006178,"amplitude":0.006178},"volumeRatio":2.1988469508579978},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX\",,,,,undefined,":{"symbol":"TLX","floatShares":272000000,"roa":"2.71%","roe":"7.36%","lyrEps":-0.0211,"volumeRatio":2.1988469508579978,"shares":339000000,"dividePrice":0,"high":11.39,"amplitude":0.016103,"preClose":12.42,"low":11.19,"week52Low":6.28,"pbRate":"7.88","psRate":"4.31","week52High":12.5999,"institutionHeld":0,"latestPrice":11.33,"eps":-0.0211,"divideRate":0,"volume":299625,"delay":0,"ttmEps":-0.0211,"open":11.34,"prevYearClose":7.49,"prevWeekClose":11.82,"prevMonthClose":9.89,"prevQuarterClose":11.53,"fiveDayClose":11.82,"twentyDayClose":10.22,"sixtyDayClose":9.74},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-02-19","symbol":"TLX","fiscalQuarterEnding":"2025/12","expectedEps":0.04,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1771477200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-08-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post-Mkt","type":"earning","dateTimestamp":1755662400000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2025-02-20","symbol":"TLX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1740027600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"TLX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.6,"buy":0.4,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.6,"analysts":5,"updateTime":1758254400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/TLX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"TLX","date":"2026-08-21","current":-536.966825,"percent":0.281179,"low":-584.49693,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"high":383.853933,"avg":21.978205,"sd":314.696392,"marketCap":3778875522.96},"quantilePoints":[{"date":"2024-11-15","current":155.824924,"twenty":155.852142,"median":155.89297,"eighty":156.178762,"marketCap":4970652360.72},{"date":"2024-11-22","current":153.647458,"twenty":154.191824,"median":155.858947,"eighty":156.314854,"marketCap":4920980791.17},{"date":"2024-11-29","current":168.345354,"twenty":154.8995,"median":156.063085,"eighty":158.49232,"marketCap":5381208976.41},{"date":"2024-12-06","current":169.502133,"twenty":155.171684,"median":156.641474,"eighty":168.045953,"marketCap":5368295184.8},{"date":"2024-12-13","current":166.916392,"twenty":155.838533,"median":162.3233,"eighty":168.045953,"marketCap":5240175366.69},{"date":"2024-12-20","current":168.345354,"twenty":155.961016,"median":166.508117,"eighty":168.916939,"marketCap":5183140063.85},{"date":"2024-12-27","current":169.774316,"twenty":156.233199,"median":167.052484,"eighty":169.706271,"marketCap":5196235069.7},{"date":"2025-01-03","current":162.241165,"twenty":156.342072,"median":167.052484,"eighty":169.542961,"marketCap":4949346723.31},{"date":"2025-01-10","current":163.261978,"twenty":156.5326,"median":167.392713,"eighty":169.228803,"marketCap":4970930045.19},{"date":"2025-01-17","current":180.956065,"twenty":158.029608,"median":167.50507,"eighty":169.864326,"marketCap":5535715919.89},{"date":"2025-01-24","current":187.353158,"twenty":159.608271,"median":167.889662,"eighty":170.577257,"marketCap":5785750657.37},{"date":"2025-01-31","current":199.670965,"twenty":161.249345,"median":168.229933,"eighty":175.407845,"marketCap":6122321793.53},{"date":"2025-02-07","current":198.349538,"twenty":162.241165,"median":168.549491,"eighty":182.861582,"marketCap":6131109878.71},{"date":"2025-02-14","current":185.473256,"twenty":162.64949,"median":169.046583,"eighty":187.353158,"marketCap":5747906307.1},{"date":"2025-02-21","current":203.261161,"twenty":163.302811,"median":169.706271,"eighty":187.353158,"marketCap":6486347833.54},{"date":"2025-02-28","current":187.883767,"twenty":163.584606,"median":170.12499,"eighty":192.087093,"marketCap":5864055113.17},{"date":"2025-03-07","current":182.602424,"twenty":164.112905,"median":170.795004,"eighty":190.960114,"marketCap":5800401146.04},{"date":"2025-03-14","current":179.829719,"twenty":164.766144,"median":174.911776,"eighty":189.692293,"marketCap":5647282174.13},{"date":"2025-03-21","current":184.714961,"twenty":166.589772,"median":175.670662,"eighty":188.147066,"marketCap":5803981960.09},{"date":"2025-03-28","current":187.327482,"twenty":166.94361,"median":178.971501,"eighty":190.960114,"marketCap":5900183330.18},{"date":"2025-04-04","current":159.860903,"twenty":166.94361,"median":178.262158,"eighty":189.692293,"marketCap":5073492527.81},{"date":"2025-04-11","current":177.179731,"twenty":166.589772,"median":177.679515,"eighty":188.147066,"marketCap":5496976372.28},{"date":"2025-04-17","current":173.797147,"twenty":166.916392,"median":177.619467,"eighty":187.883767,"marketCap":5535140863.85},{"date":"2025-04-25","current":193.309359,"twenty":167.052484,"median":178.059203,"eighty":190.062144,"marketCap":6172717887.8},{"date":"2025-05-02","current":198.453445,"twenty":167.392713,"median":178.295984,"eighty":190.062144,"marketCap":6327668326.52},{"date":"2025-05-09","current":181.396737,"twenty":167.481337,"median":179.235568,"eighty":190.062144,"marketCap":5809793224.05},{"date":"2025-05-16","current":176.029393,"twenty":167.481337,"median":178.295984,"eighty":189.78972,"marketCap":5619140101.04},{"date":"2025-05-23","current":172.647682,"twenty":167.528804,"median":178.059203,"eighty":189.451294,"marketCap":5528513460.13},{"date":"2025-05-30","current":176.779306,"twenty":167.780801,"median":177.456621,"eighty":188.460572,"marketCap":5687082652.57},{"date":"2025-06-06","current":173.121803,"twenty":167.88049,"median":177.318176,"eighty":187.949592,"marketCap":5638091901.1},{"date":"2025-06-13","current":167.838743,"twenty":167.88049,"median":176.508379,"eighty":187.45928,"marketCap":5463186103.94},{"date":"2025-06-20","current":168.923551,"twenty":167.889662,"median":176.029393,"eighty":187.353158,"marketCap":5442074695.06},{"date":"2025-06-27","current":165.669807,"twenty":167.592888,"median":175.625224,"eighty":187.337752,"marketCap":5412704421.76},{"date":"2025-07-03","current":162.348276,"twenty":167.428163,"median":175.082406,"eighty":187.024133,"marketCap":5325445922.59},{"date":"2025-07-11","current":163.297285,"twenty":166.671427,"median":174.480785,"eighty":186.439488,"marketCap":5350247552.51},{"date":"2025-07-18","current":171.228286,"twenty":165.90028,"median":173.909122,"eighty":186.045921,"marketCap":5541358073.91},{"date":"2025-07-25","current":144.045965,"twenty":165.670181,"median":173.731386,"eighty":185.637634,"marketCap":4750367012.62},{"date":"2025-08-01","current":136.589468,"twenty":164.955304,"median":173.25664,"eighty":185.381192,"marketCap":4384547406.6},{"date":"2025-08-08","current":119.575098,"twenty":163.364827,"median":173.121803,"eighty":185.031841,"marketCap":3879545892.37},{"date":"2025-08-15","current":118.626089,"twenty":162.985468,"median":172.816584,"eighty":184.520886,"marketCap":3844757658.1},{"date":"2025-08-22","current":367.342977,"twenty":162.565192,"median":172.783145,"eighty":185.031841,"marketCap":3983594342.69},{"date":"2025-08-29","current":297.28853,"twenty":162.917681,"median":173.086118,"eighty":186.439488,"marketCap":3223899680.91},{"date":"2025-09-05","current":280.194275,"twenty":162.97191,"median":173.155042,"eighty":187.353158,"marketCap":3038523660.62},{"date":"2025-09-12","current":284.24913,"twenty":163.053254,"median":173.392729,"eighty":189.722035,"marketCap":3082495919.22},{"date":"2025-09-19","current":299.993591,"twenty":163.181765,"median":173.840405,"eighty":192.411646,"marketCap":3253234303.96},{"date":"2025-09-26","current":303.368871,"twenty":163.269039,"median":174.34097,"eighty":195.332201,"marketCap":3289837005.56},{"date":"2025-10-03","current":316.222238,"twenty":163.331056,"median":174.844246,"eighty":197.182743,"marketCap":3429223360.77},{"date":"2025-10-10","current":308.943311,"twenty":163.584606,"median":175.579785,"eighty":198.432664,"marketCap":3350288154.24},{"date":"2025-10-17","current":337.724829,"twenty":164.112905,"median":175.99796,"eighty":200.117317,"marketCap":3662404902.51},{"date":"2025-10-24","current":335.676999,"twenty":164.422238,"median":176.508379,"eighty":204.373856,"marketCap":3640197520.67},{"date":"2025-10-31","current":328.898919,"twenty":164.871944,"median":177.318176,"eighty":280.077091,"marketCap":3566693671.28},{"date":"2025-11-07","current":302.845362,"twenty":165.230483,"median":178.059203,"eighty":285.744085,"marketCap":3284159889.46},{"date":"2025-11-14","current":289.051675,"twenty":165.371547,"median":178.295984,"eighty":290.299055,"marketCap":3134576370.19},{"date":"2025-11-21","current":278.19044,"twenty":165.561349,"median":179.014446,"eighty":289.541689,"marketCap":3016793389.39},{"date":"2025-11-28","current":310.533522,"twenty":165.669807,"median":179.412236,"eighty":291.060611,"marketCap":3367532955.32},{"date":"2025-12-05","current":306.208941,"twenty":165.670741,"median":180.00406,"eighty":294.691227,"marketCap":3320635708.33},{"date":"2025-12-12","current":286.055209,"twenty":165.873166,"median":180.584513,"eighty":295.905706,"marketCap":3102081667.78},{"date":"2025-12-19","current":244.707348,"twenty":165.940952,"median":181.091444,"eighty":294.691227,"marketCap":2653691145.03},{"date":"2025-12-26","current":248.848958,"twenty":166.394684,"median":181.60348,"eighty":294.390689,"marketCap":2698604201.29},{"date":"2026-01-02","current":236.757004,"twenty":166.574536,"median":182.507221,"eighty":293.840477,"marketCap":2567474872.89},{"date":"2026-01-09","current":234.880062,"twenty":166.797362,"median":182.734458,"eighty":292.111558,"marketCap":2547120662.92},{"date":"2026-01-16","current":240.619616,"twenty":166.998047,"median":183.212494,"eighty":291.104403,"marketCap":2609362374.53},{"date":"2026-01-23","current":233.793317,"twenty":167.188576,"median":183.578507,"eighty":290.823686,"marketCap":2535335622.99},{"date":"2026-01-30","current":230.611959,"twenty":167.428163,"median":183.988776,"eighty":290.419247,"marketCap":2500835870.83},{"date":"2026-02-06","current":214.320895,"twenty":167.500324,"median":184.979028,"eighty":290.056234,"marketCap":2324169939.4},{"date":"2026-02-13","current":194.105832,"twenty":167.571527,"median":185.74722,"eighty":289.461299,"marketCap":2104950801.53},{"date":"2026-02-20","current":-349.931165,"twenty":167.550165,"median":186.245055,"eighty":289.186438,"marketCap":2493259551.93},{"date":"2026-02-27","current":-337.576812,"twenty":166.94361,"median":185.358176,"eighty":288.884688,"marketCap":2405234781.68},{"date":"2026-03-06","current":-357.014534,"twenty":165.886723,"median":184.229774,"eighty":287.796958,"marketCap":2543728559.75},{"date":"2026-03-13","current":-380.87359,"twenty":165.371547,"median":183.661424,"eighty":286.105301,"marketCap":2713724328.68},{"date":"2026-03-20","current":-427.441295,"twenty":164.112905,"median":183.427298,"eighty":285.888656,"marketCap":3045519229.47},{"date":"2026-03-27","current":-448.04178,"twenty":163.181765,"median":182.800475,"eighty":285.212188,"marketCap":3192297684.03},{"date":"2026-04-02","current":-425.435204,"twenty":162.890567,"median":182.629922,"eighty":285.17117,"marketCap":3031225831.43},{"date":"2026-04-10","current":-492.382264,"twenty":161.467054,"median":181.810223,"eighty":284.24913,"marketCap":3508223631.57},{"date":"2026-04-17","current":-499.465833,"twenty":158.955031,"median":181.091444,"eighty":284.07528,"marketCap":3558694058.36},{"date":"2026-04-24","current":-507.89561,"twenty":156.233199,"median":180.584513,"eighty":282.031139,"marketCap":3618756217.23},{"date":"2026-05-01","current":-532.518745,"twenty":154.872282,"median":180.00406,"eighty":281.147736,"marketCap":3794196059.21},{"date":"2026-05-08","current":-508.824558,"twenty":144.045965,"median":179.412236,"eighty":280.966174,"marketCap":3625374971.37},{"date":"2026-05-15","current":-506.065728,"twenty":140.182144,"median":178.86094,"eighty":280.209239,"marketCap":3605718311.9},{"date":"2026-05-22","current":-452.537308,"twenty":125.947014,"median":178.262158,"eighty":280.194275,"marketCap":3224328322.29},{"date":"2026-05-29","current":-444.681415,"twenty":120.122064,"median":178.059203,"eighty":279.725537,"marketCap":3168355079.47},{"date":"2026-06-05","current":-452.683664,"twenty":115.968865,"median":177.318176,"eighty":279.589795,"marketCap":3225371110.32},{"date":"2026-06-12","current":-453.131496,"twenty":29.784924,"median":176.508379,"eighty":278.469383,"marketCap":3228561906.13},{"date":"2026-06-18","current":-479.232706,"twenty":-319.885885,"median":176.029393,"eighty":275.361846,"marketCap":3414533028.17},{"date":"2026-06-26","current":-505.22407,"twenty":-336.088027,"median":175.625224,"eighty":265.637187,"marketCap":3599721496.58},{"date":"2026-07-02","current":-567.292731,"twenty":-347.690038,"median":175.082406,"eighty":259.576863,"marketCap":4041960704.33},{"date":"2026-07-10","current":-538.02731,"twenty":-371.335373,"median":174.480785,"eighty":256.751103,"marketCap":3833444584.84},{"date":"2026-07-17","current":-497.824928,"twenty":-406.861587,"median":173.909122,"eighty":252.484997,"marketCap":3547002606.6},{"date":"2026-07-24","current":-487.362208,"twenty":-419.925535,"median":173.731386,"eighty":249.449835,"marketCap":3472455733.71},{"date":"2026-07-31","current":-475.018244,"twenty":-425.317007,"median":173.324997,"eighty":249.116107,"marketCap":3384504988.78},{"date":"2026-08-07","current":-543.110083,"twenty":-431.380818,"median":173.121803,"eighty":248.587668,"marketCap":3869659340.88},{"date":"2026-08-14","current":-563.285348,"twenty":-444.416873,"median":172.850024,"eighty":247.242146,"marketCap":4013408103.64},{"date":"2026-08-21","current":112.812357,"twenty":-445.662886,"median":172.57995,"eighty":245.774025,"marketCap":3778875522.96}],"updateTime":1787483231630},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2625964685","title":"Telix Pharmaceuticals US PSMA PET Sales Gain Traction, Seen to Grow Market Share, Says Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2625964685","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625964685?lang=en_us&edition=fundamental","pubTime":"2026-04-08 06:44","pubTimestamp":1775601847,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  reported strong US PSMA PET diagnostic sales in the first quarter, with a 5% rise, as focus shifts to regulatory updates for its investigational imaging agents Pixclara and Zircaix, Jefferies said Tuesday in a note.Jefferies expects the company to grow its PSMA PET diagnostic market share over the medium term, driven by approval of Gozellix product, which is projected to expand its addressable US PET scanners by 15%.The brokerage boosted its fiscal 2026 net profit after tax estimate to $3.3 million from $2 million, also updating its forecast for US and EU PSMA PET diagnostic sales, including US volumes of around 134,200 doses, up from 133,000 doses expected before.The company maintained its fiscal 2026 revenue guidance of $950 million to $970 million, compared with Jefferies' forecast of $965 million.Jefferies kept its buy rating and raised its price target to AU$24.30 from AU$23.40.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625950201","title":"Why Is Telix Pharma Stock Soaring Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625950201","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625950201?lang=en_us&edition=fundamental","pubTime":"2026-04-08 01:56","pubTimestamp":1775584600,"startTime":"0","endTime":"0","summary":"Telix Pharma stock climbs on strong Q1 growth and Phase 3 study success. Analysts maintain Buy ratings with price targets up to $22.00.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/04/51688276/why-is-telix-pharma-stock-soaring-tuesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953447","title":"Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday Ahead of Trump's Hormuz Reopening Deadline","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953447","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625953447?lang=en_us&edition=fundamental","pubTime":"2026-04-07 21:01","pubTimestamp":1775566895,"startTime":"0","endTime":"0","summary":"The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was down 0.6% and the actively traded Invesco QQQ Trust (QQQ) was 0.7% lower in Tuesday's premarket activity, ahead of US President D","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["RDW","XLY","NMR","XRT","FAZ","RTH","IPK","SOXX","EEM","IGM","USO","TLX",".DJI","EQR","EETH","XLK","XLP","IYK","RTH.AU","VDC","EXI","XLI","BETH","VIS","VHT.AU","QQQ","VHT","XLE","MNR","INFY","TSLA","XLV","PMR","UNG","GLD","FDN","BITO","FAS","SPY.AU","IVV","IBB","IYE","SLV","TLX.AU","XSD","IYH","IYJ","IYW","SPY","XLF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625266932","title":"Telix Pharmaceuticals Price Target Maintained With a $20.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2625266932","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625266932?lang=en_us&edition=fundamental","pubTime":"2026-04-07 19:15","pubTimestamp":1775560500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/TLX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 07, 2026 07:15 ET (11:15 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625985536","title":"Telix Pharmaceuticals Q1 Revenue Rises 24%; Shares Gain 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625985536","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625985536?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:57","pubTimestamp":1775527077,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) reported first-quarter revenue of $230 million, up 24% from a year earlier, according to a Tuesday filing with the Australian bourse.First-quarter revenue for the compa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625830539","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (OtherCMXHF) and Telix Pharmaceuticals (OtherTLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2625830539","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625830539?lang=en_us&edition=fundamental","pubTime":"2026-04-07 09:40","pubTimestamp":1775526003,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on CSL (CMXHF) and Telix Pharmaceuticals (TLPPF). CSL (CMXHF) Macqua...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-csl-othercmxhf-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-csl-othercmxhf-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LABU","BK4581","LU1169590202.USD","CMXHF","BK4137","HCSG","BK4585","SGXZ23171101.USD","BK4588","CSL","TLPPF","BK4086","LU0029874061.USD","TLX","XLV","BK4139","LU0728928796.USD","SG9999004303.SGD","LU1169589451.USD","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625233628","title":"Will Telix (ASX:TLX) Board Refresh Subtly Recast Its Governance And Growth Balancing Act?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625233628","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625233628?lang=en_us&edition=fundamental","pubTime":"2026-04-06 04:12","pubTimestamp":1775419922,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals recently announced that David Gill will join its Board as a Non-Executive Director on 11 May 2026, with plans for him to succeed Dr. Mark Nelson as Chair while Nelson remains a Non-Executive Director.\nThe appointment brings a veteran life sciences executive with extensive radiopharmaceutical, capital markets and governance experience onto Telix’s Board, potentially reshaping how the company balances growth ambitions with oversight as a dual-listed business.\nWe’ll now...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/will-telix-asxtlx-board-refresh-subtly-recast-its-governance","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624652093","title":"Citi Group Entities Exit Substantial Holder Status in Telix Pharmaceuticals","url":"https://stock-news.laohu8.com/highlight/detail?id=2624652093","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624652093?lang=en_us&edition=fundamental","pubTime":"2026-04-02 13:39","pubTimestamp":1775108345,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an announcement. Citigroup Global Markets Australia and related Citi group entities have notified Te...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/citi-group-entities-exit-substantial-holder-status-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/citi-group-entities-exit-substantial-holder-status-in-telix-pharmaceuticals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","LU0314106906.USD","BK4585","LU0130517989.USD","LU2125154778.USD","LU0310800965.SGD","LU1668664300.SGD","LU1267930227.SGD","LU2236285917.USD","LU2462157665.USD","LU1201861249.SGD","BK4588","LU0052756011.USD","LU2125154935.USD","BK4504","BK4566","LU1244550494.USD","LU1162221912.USD","BK4559","LU0170899867.USD","LU0072461881.USD","IE00BSNM7G36.USD","LU1244550221.USD","LU0106831901.USD","LU1244550577.SGD","LU2417539215.USD","LU2456880835.USD","LU0162691827.USD","LU0130102774.USD","LU0098860793.USD","LU0320765646.SGD","LU1506573853.SGD","LU1366192091.USD","BK4534","LU0980610538.SGD","LU0648001328.SGD","TLX","BK4139","LU2360032135.SGD","LU1791807156.HKD","LU0128525689.USD","LU0477156953.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624547779","title":"Telix Appoints David Gill as Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2624547779","media":"prnewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624547779?lang=en_us&edition=fundamental","pubTime":"2026-04-02 06:59","pubTimestamp":1775084340,"startTime":"0","endTime":"0","summary":"Mr. Gill brings deep expertise in capital markets, scaling businesses, governance and corporate turn-around strategy and has served as Chief Financial Officer or President of multiple publicly traded companies, including EndoChoiceHoldings, Inc. , INC Research , and CTI Molecular Imaging . He holds a B.S. in Accounting from Wake Forest University and an MBA from Emory University.Telix Interim Chair, Mark Nelson, commented, \"We are pleased to welcome David to the Board, where his strong financial expertise and deep knowledge of U.S. capital markets will be highly valuable. We intend to further strengthen the Board through additional appointments aligned with our growth trajectory and governance needs as a dual-listed company.\". Telix Investor Relations Ms. Charlene JawAssociate Director Investor Relations[emailprotected]","market":"fut","thumbnail":"https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300","type":0,"news_type":0,"thumbnails":["https://mma.prnewswire.com/media/1920208/Telix_Main_Logo_Logo.jpg?w=300"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.prnewswire.com/apac/news-releases/telix-appoints-david-gill-as-non-executive-director-302732101.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SEC.AU","QID","QQQM","JEPQ","PSQ","NVIW.SI","BK4526","SBBP","TQQQ","BK7039","NQmain","QQQ","BK7067","NDX","ASX.AU","YMAB","EOLS","GPIQ","ASX","BK4543","TLX.AU","QQQJ","IYW","BK4007","FTEC",".IXIC","QYLG","INCR","TLX","QDTE","BK4141","BK4139","QLD","MNQmain","QQQY","SQQQ","QQQE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622809302","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 7.1% After Resubmitting TLX101-Px NDA With FDA Fast Track Designation - Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2622809302","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622809302?lang=en_us&edition=fundamental","pubTime":"2026-03-28 07:14","pubTimestamp":1774653245,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara, 18F-FET), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment effects in adult and pediatric patients, incorporating additional data and analysis requested after a prior Complete Response Letter.\nThe filing is significant because TLX101-Px holds both Orphan Drug and Fast Track designations and could become the first FDA-approved...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-71-after-resubmitting-tlx","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK7067","TLX.AU","TLX","BK4588","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622895939","title":"ASX Growth Companies With Insider Ownership Up To 38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622895939","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622895939?lang=en_us&edition=fundamental","pubTime":"2026-03-27 03:08","pubTimestamp":1774552107,"startTime":"0","endTime":"0","summary":"As the Australian stock market experiences a modest rise amidst geopolitical uncertainties, investors are keeping a close watch on sectors poised for growth and resilience. In such an environment, companies with high insider ownership often attract attention due to the confidence they signal in their own potential, making them intriguing prospects for those seeking long-term growth opportunities.","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6033000-choice1-main-header/1585186824821"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-reg/regis-healthcare-shares/news/asx-growth-companies-with-insider-ownership-up-to-38-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["REG.AU","AR1.AU","BK7007","FRS.AU","BK7017","BK7129","TLX","AV1.AU","BK7104","BK7095","BK7067","TLX.AU","AEM.AU","BK7016","BK7110","BK4526","BK7113","BK4139","CYC.AU","BK4531","BK4108","EIQ.AU","MAU.AU","TOR.AU","BK4552","CUV.AU","IQ","FEX.AU","BK7508","BK4505"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621507720","title":"A Look At Telix Pharmaceuticals (ASX:TLX) Valuation After Key TLX101-Px And TLX591-Tx Trial Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2621507720","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621507720?lang=en_us&edition=fundamental","pubTime":"2026-03-23 12:27","pubTimestamp":1774240038,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) has entered a busy regulatory phase, resubmitting its TLX101-Px New Drug Application for glioma imaging while also reporting that the lead-in stage of its TLX591-Tx Phase 3 prostate cancer trial met safety objectives.\nSee our latest analysis for Telix Pharmaceuticals.\nThese regulatory updates come after a strong short term run, with a 1 month share price return of 22.24% and a 7 day share price return of 12.93%. However, the 1 year total shareholder return is...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-asxtlx-valuation-after-key-t","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX","TLX.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621183756","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 12.9% After TLX101-Px NDA Resubmission and U.S. Build-Out News – Has The Bull Case Changed?","url":"https://stock-news.laohu8.com/highlight/detail?id=2621183756","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621183756?lang=en_us&edition=fundamental","pubTime":"2026-03-21 01:13","pubTimestamp":1774026782,"startTime":"0","endTime":"0","summary":"In March 2026, Telix Pharmaceuticals resubmitted its New Drug Application to the FDA for TLX101-Px (Pixclara), an investigational PET imaging agent for distinguishing recurrent or progressive glioma from treatment-related changes in adults and children, incorporating additional data requested after a prior Complete Response Letter and supported by Orphan Drug and Fast Track designations.\nA key differentiator is that 18F-FET imaging like TLX101-Px is already referenced in international glioma...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-129-after-tlx101-px-nda-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX.AU","TLX","BK7067","BK4139","BGSX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620202561","title":"Telix Pharmaceuticals Says Citigroup Lifts Stake","url":"https://stock-news.laohu8.com/highlight/detail?id=2620202561","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620202561?lang=en_us&edition=fundamental","pubTime":"2026-03-20 13:17","pubTimestamp":1773983826,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) received notice that Citigroup and its affiliates increased their holdings in the company to 6.0668% from 5.0639%, according to a Friday filing with the Australian bourse.Citigroup and its affiliates now own 20.6 million shares in the company, the filing said.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","TLX.AU","TLX","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620327449","title":"Telix Issues New Deferred Share Rights Under Employee Incentive Scheme","url":"https://stock-news.laohu8.com/highlight/detail?id=2620327449","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620327449?lang=en_us&edition=fundamental","pubTime":"2026-03-20 05:53","pubTimestamp":1773957200,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has shared an update. Telix Pharmaceuticals has notified the market of the issue of 126,668 new unquoted securi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-deferred-share-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-issues-new-deferred-share-rights-under-employee-incentive-scheme?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620291040","title":"UBS Remains a Buy on Telix Pharmaceuticals (TLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2620291040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620291040?lang=en_us&edition=fundamental","pubTime":"2026-03-19 08:35","pubTimestamp":1773880555,"startTime":"0","endTime":"0","summary":"UBS analyst David Dai maintained a Buy rating on Telix Pharmaceuticals today and set a price target of A$31.00. According to TipRanks, Dai is a 3-s...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ubs-remains-a-buy-on-telix-pharmaceuticals-tlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TLPPF","IE0034235071.USD","TLX","UBS","BK4585","BK4118","BK4588","LU3187612489.SGD","LU1863844749.USD","BK4534","BK4139","LU1829250122.USD","LU1863844665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619648928","title":"Analysts Offer Insights on Healthcare Companies: Apogee Therapeutics (APGE), Wave Life Sciences (WVE) and Telix Pharmaceuticals (OtherTLPPF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2619648928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619648928?lang=en_us&edition=fundamental","pubTime":"2026-03-16 07:30","pubTimestamp":1773617411,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Apogee Therapeutics (APGE – Research Report), Wave L...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apogee-therapeutics-apge-wave-life-sciences-wve-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-apogee-therapeutics-apge-wave-life-sciences-wve-and-telix-pharmaceuticals-othertlppf-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","APGE","BK4588","BK4139","BK4007","HCSG","TLX","WVE","XLV","XBI","BK4581","LU0029874061.USD","LU0128526141.USD","BK4137","LABU","LU0053671581.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619863514","title":"Telix Resubmits U.S. FDA Application for Glioma Imaging Agent TLX101-Px","url":"https://stock-news.laohu8.com/highlight/detail?id=2619863514","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619863514?lang=en_us&edition=fundamental","pubTime":"2026-03-16 06:08","pubTimestamp":1773612488,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals ( ($AU:TLX) ) has issued an announcement. Telix Pharmaceuticals has resubmitted a New Drug Application to the U.S. FDA for TL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/telix-resubmits-u-s-fda-application-for-glioma-imaging-agent-tlx101-px?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/telix-resubmits-u-s-fda-application-for-glioma-imaging-agent-tlx101-px?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LABU","TLX","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619170812","title":"A Look At Telix Pharmaceuticals’ Valuation After ProstACT Global Phase 3 TLX591-Tx Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2619170812","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619170812?lang=en_us&edition=fundamental","pubTime":"2026-03-15 11:34","pubTimestamp":1773545683,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) is back in focus after announcing that Part 1 of its ProstACT Global Phase 3 trial for TLX591-Tx met key safety and tolerability endpoints, clearing the way for the study's expansion.\nSee our latest analysis for Telix Pharmaceuticals.\nThe ProstACT Global update comes after a strong 30 day share price return of 24.34% and a 7 day share price return of 5.02%. However, the 1 year total shareholder return shows a decline of 58.55% and the year to date share price...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-after-prostact-glo","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/a-look-at-telix-pharmaceuticals-valuation-after-prostact-glo","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["TLX","TLX.AU","BK7067","USD","USD.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619474195","title":"Telix Pharmaceuticals (ASX:TLX) Is Up 11.3% After Positive Phase 3 TLX591-Tx Safety Data - What's Changed","url":"https://stock-news.laohu8.com/highlight/detail?id=2619474195","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619474195?lang=en_us&edition=fundamental","pubTime":"2026-03-13 14:36","pubTimestamp":1773383783,"startTime":"0","endTime":"0","summary":"In early March 2026, Telix Pharmaceuticals reported that Part 1 of its ProstACT Global Phase 3 trial for TLX591-Tx in metastatic castration-resistant prostate cancer met its primary safety and dosimetry objectives, with an acceptable tolerability profile and no new safety signals across combinations with standard-of-care therapies.\nA distinctive aspect for investors is that TLX591-Tx’s antibody-based design showed minimal kidney, salivary and lacrimal gland exposure versus existing...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-113-after-positive-phase","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-tlx/telix-pharmaceuticals-shares/news/telix-pharmaceuticals-asxtlx-is-up-113-after-positive-phase","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7067","TLX.AU","BK4139","TLX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":199,"code":"91000000","status":"200"}]}}